RGEN (Repligen) Cyclically Adjusted FCF per Share: $1.14 (As of Mar. 2026)


RGEN Repligen Corp RGEN
84 GF Score
Price $141.45
GF Value $176.53
Valuation Modestly Undervalued
! 5 Warning Signs
View Full Analysis

What is Repligen Cyclically Adjusted FCF per Share?

Repligen RGEN -0.66% 84 Cyclically Adjusted FCF per Share is $1.14 as of Mar. 2026. GuruFocus rates RGEN with a GF Score™ of 84/100 and a GF Value™ of $176.53 (Modestly Undervalued). The stock has 5 warning signs investors should review.

E10 is a concept invented by Prof. Robert Shiller, who uses E10 for his Shiller PE Ratio calculation. E10 is the average of the inflation adjusted earnings of a company over the past 10 years. The similar calculation is applied by GuruFocus to calculate the Cyclically Adjusted FCF per Share and the Cyclically Adjusted Price-to-FCF. The Cyclically Adjusted FCF per Share is the average of the inflation adjusted Free Cash Flow per Share of a company over the past 10 years.

Repligen's adjusted free cash flow per share for the three months ended in Mar. 2026 was $0.412. Add all the adjusted free cash flow per share for the past 10 years together and divide the count will get our Cyclically Adjusted FCF per Share, which is $1.14 for the trailing ten years ended in Mar. 2026.

During the past 12 months, Repligen's average Cyclically Adjusted FCF Growth Rate was 17.50% per year. During the past 3 years, the average Cyclically Adjusted FCF Growth Rate was 19.60% per year. During the past 5 years, the average Cyclically Adjusted FCF Growth Rate was 17.70% per year. During the past 10 years, the average Cyclically Adjusted FCF Growth Rate was 14.00% per year. Please click Growth Rate Calculation Example (GuruFocus) to see how GuruFocus calculates Wal-Mart Stores Inc (WMT)'s revenue growth rate. You can apply the same method to get the Cyclically Adjusted FCF Growth Rate using Cyclically Adjusted FCF per Share data.

During the past 13 years, the highest 3-Year average Cyclically Adjusted FCF Growth Rate of Repligen was 146.60% per year. The lowest was -6.30% per year. And the median was 18.45% per year.

As of today (2026-07-06), Repligen's current stock price is $141.45. Repligen's Cyclically Adjusted FCF per Share for the quarter that ended in Mar. 2026 was $1.14. Repligen's Cyclically Adjusted Price-to-FCF of today is 124.08.

During the past 13 years, the highest Cyclically Adjusted Price-to-FCF of Repligen was 621.65. The lowest was 75.17. And the median was 225.33.


Repligen  (NAS:RGEN) Cyclically Adjusted FCF per Share Explanation

If a company grows much fast than inflation, Cyclically Adjusted FCF per Share may underestimate the company's free cash flow. Cyclically Adjusted Price-to-FCF can seem to be too high even the actual Price-to-Free-Cash-Flow is low.

For the Cyclically Adjusted Price-to-FCF, the free cash flow per share of the past 10 years are inflation-adjusted and averaged. The result is used for P/FCF calculation. Since it looks at the average over the last 10 years, the Cyclically Adjusted Price-to-FCF is also called CAPFCF Ratio.

The Shiller PE Ratio was first used by professor Robert Shiller. He uses E10 for his Shiller PE Ratio calculation. E10 is the average of the inflation adjusted earnings per share of a company over the past 10 years. The similar calculation is applied by GuruFocus to calculate the Cyclically Adjusted Price-to-FCF. The Cyclically Adjusted FCF per Share is the average of the inflation adjusted free cash flow per share of a company over the past 10 years.

Repligen's Cyclically Adjusted Price-to-FCF of today is calculated as

Cyclically Adjusted Price-to-FCF=Share Price/Cyclically Adjusted FCF per Share
=141.45/1.14
=124.08

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

During the past 13 years, the highest Cyclically Adjusted Price-to-FCF of Repligen was 621.65. The lowest was 75.17. And the median was 225.33.


Be Aware

Cyclically Adjusted Price-to-FCF works better for cyclical companies. It gives you a better idea on the company's real free cash flow value.


Repligen Cyclically Adjusted FCF per Share Related Terms


Repligen Cyclically Adjusted FCF per Share Historical Data

* Premium members only.

The historical data trend for Repligen's Cyclically Adjusted FCF per Share can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Repligen Cyclically Adjusted FCF per Share Chart

Repligen Annual Data
Trend Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23 Dec24 Dec25
Cyclically Adjusted FCF per Share
Get a 7-Day Free Trial Premium Member Only Premium Member Only 0.57 0.62 0.69 0.92 1.06

Repligen Quarterly Data
Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24 Mar25 Jun25 Sep25 Dec25 Mar26
Cyclically Adjusted FCF per Share Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 0.97 0.98 1.04 1.06 1.14

RGEN vs ATR, AVTR, TFX: Cyclically Adjusted FCF per Share Comparison

For the Medical Instruments & Supplies subindustry, Repligen's Cyclically Adjusted Price-to-FCF, along with its competitors' market caps and Cyclically Adjusted Price-to-FCF data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Repligen Cyclically Adjusted Price-to-FCF vs Medical Devices & Instruments Industry

For the Medical Devices & Instruments industry and Healthcare sector, Repligen's Cyclically Adjusted Price-to-FCF distribution charts can be found below:

* The bar in red indicates where Repligen's Cyclically Adjusted Price-to-FCF falls into.


RGEN
84GF Score
Repligen Corp RGEN
Cyclically Adjusted FCF per Share is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Repligen Cyclically Adjusted FCF per Share Calculation

E10 is a concept invented by Prof. Robert Shiller, who uses E10 for his Shiller PE Ratio calculation. E10 is the average of the inflation adjusted earnings of a company over the past 10 years. The similar calculation is applied by GuruFocus to calculate the Cyclically Adjusted FCF per Share and the Cyclically Adjusted Price-to-FCF. The Cyclically Adjusted FCF per Share is the average of the inflation adjusted Free Cash Flow per Share of a company over the past 10 years.

What is Cyclically Adjusted FCF per Share? How do we calculate Cyclically Adjusted FCF per Share?

Cyclically Adjusted FCF per Share is the average of the inflation adjusted Free Cash Flow per Share of a company over the past 10 years. Let's use an example to explain.

If we want to calculate the Cyclically Adjusted FCF per Share of Wal-Mart (WMT) for Dec. 31, 2010, we need to have the inflation data and the free cash flow per share from 2001 through 2010.

We adjusted the 2001 free cash flow per share data with the total inflation from 2001 through 2010 to the equivalent free cash flow in 2010. If the total inflation from 2001 to 2010 is 40%, and Wal-Mart's free cash flow is $1 a share in 2001, then the 2001's equivalent free cash flow in 2010 is $1.4 a share. If Wal-Mart's free cash flow is $1 again in 2002, and the total inflation from 2002 through 2010 is 35%, then the equivalent 2002 free cash flow in 2010 is $1.35. So on and so forth, you get the equivalent free cash flow per share of past 10 years. Then you add them together and divided the sum by the count to get Cyclically Adjusted FCF per Share.

Please note that we use the CPI data of the country/region where the company is headquartered. If the CPI data for that country/region is not available, then we will use the CPI data of the United States as default.

For example, Repligen's adjusted Free Cash Flow per Share data for the three months ended in Mar. 2026 was:

Adj_FreeCashFlowPerShare= Free Cash Flow per Share /CPI of Mar. 2026 (Change)*Current CPI (Mar. 2026)
=0.412/330.2130*330.2130
=0.412

Current CPI (Mar. 2026) = 330.2130.

Repligen Quarterly Data

Free Cash Flow per Share CPI Adj_FreeCashFlowPerShare
201606 0.281 241.018 0.385
201609 -0.094 241.428 -0.129
201612 0.032 241.432 0.044
201703 -0.004 243.801 -0.005
201706 0.041 244.955 0.055
201709 -0.064 246.819 -0.086
201712 0.303 246.524 0.406
201803 0.000 249.554 0.000
201806 0.069 251.989 0.090
201809 0.338 252.439 0.442
201812 0.002 251.233 0.003
201903 0.129 254.202 0.168
201906 0.255 256.143 0.329
201909 0.291 256.759 0.374
201912 0.199 256.974 0.256
202003 0.085 258.115 0.109
202006 0.230 257.797 0.295
202009 0.306 260.280 0.388
202012 0.057 260.474 0.072
202103 0.003 264.877 0.004
202106 0.360 271.696 0.438
202109 0.189 274.310 0.228
202112 0.281 278.802 0.333
202203 -0.087 287.504 -0.100
202206 0.344 296.311 0.383
202209 -0.282 296.808 -0.314
202212 0.710 296.797 0.790
202303 0.030 301.836 0.033
202306 0.441 305.109 0.477
202309 0.530 307.789 0.569
202312 0.322 306.746 0.347
202403 0.643 312.332 0.680
202406 0.616 314.175 0.647
202409 0.753 315.301 0.789
202412 0.521 315.605 0.545
202503 0.187 319.799 0.193
202506 0.372 322.561 0.381
202509 0.756 324.800 0.769
202512 0.307 324.054 0.313
202603 0.412 330.213 0.412

Add all the adjusted free cash flow per share together and divide 10 will get our Cyclically Adjusted FCF per Share.

What does a Cyclically Adjusted FCF per Share of $1.14 mean?
Repligen (RGEN) has a Cyclically Adjusted FCF per Share of $1.14 as of Mar. 2026. Cyclically Adjusted FCF per Share represents the company's inflation-adjusted FCF per share over a 10-year period. View historical data on Repligen and its competitors.
Is Repligen's Cyclically Adjusted FCF per Share too high?
Repligen's current Cyclically Adjusted FCF per Share is $1.14. Overall, Repligen has a GF Score™ of 84/100 and is considered Modestly Undervalued, reflecting its overall financial health beyond just this single metric.
How does Repligen's Cyclically Adjusted FCF per Share compare to ATR and AVTR?
Repligen's Cyclically Adjusted FCF per Share of $1.14 can be compared against companies in the Medical Devices & Instruments industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Cyclically Adjusted FCF per Share for a Medical Devices & Instruments company?
A good Cyclically Adjusted FCF per Share depends on the Medical Devices & Instruments industry context. However, Cyclically Adjusted FCF per Share should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Cyclically Adjusted FCF per Share mean?
A high Cyclically Adjusted FCF per Share can signal that a stock is expensive relative to its fundamentals. Cyclically Adjusted FCF per Share represents the company's inflation-adjusted FCF per share over a 10-year period. View historical data on Repligen and its competitors. Repligen's current Cyclically Adjusted FCF per Share is $1.14. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Repligen stock overvalued right now?
Based on GuruFocus' analysis, Repligen (RGEN) is currently considered Modestly Undervalued. The stock's GF Value™ is $176.53, compared to a current price of $141.45 — trading 19.9% below its estimated fair value. The current Cyclically Adjusted FCF per Share is $1.14. Repligen's overall GF Score™ is 84/100 with 5 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Cyclically Adjusted FCF per Share calculated?
Cyclically Adjusted FCF per Share is calculated from a company's financial statements. For Repligen (RGEN), the current Cyclically Adjusted FCF per Share is $1.14 as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Is Repligen (RGEN) Overvalued in 2026?

Based on GuruFocus' analysis, Repligen stock appears to be undervalued. The current stock price of $141.45 is trading 19.9% below its estimated GF Value™ of $176.53. GuruFocus considers Repligen to be Modestly Undervalued.

Key valuation signals for RGEN:

  • Cyclically Adjusted FCF per Share: $1.14
  • GF Value™: $176.53 vs. price of $141.45 (19.9% below fair value)
  • GF Score™: 84/100 with 5 warning signs

No single metric tells the full story. See the RGEN stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.


Repligen Business Description

Other Exchanges RGN:Germany
Address 41 Seyon Street, Building 1, Suite 100, Waltham, MA, USA, 02453
Repligen, headquartered in Waltham, Massachusetts, is a global life sciences company that develops and sells bioprocessing equipment and supplies used in the manufacturing of biologic drugs, including monoclonal antibodies, recombinant proteins, vaccines, and cell and gene therapies. Its customers include biopharmaceutical companies, contract development and manufacturing organizations, or CDMOs, and other life science companies. It sells four main product categories: filtration (including fluid management) is the largest category (about 55% of total revenue), while chromatography, proteins, and process analytics are 21%, 11%, and 13%, respectively. Customers in North America, Europe, and Asia Pacific contribute about 44%, 37%, and 19% of revenue, respectively.
84GF Score

Get the complete analysis for RGEN

Cyclically Adjusted FCF per Share is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

$141.45
Price
$176.53
GF Value